Resiquimod - Wikipedia
Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel [1] in the treatment of skin lesions [2] such as …
Resiquimod, a topical drug for viral skin lesions and skin cancer
Introduction: Resiquimod is an immune response modifier which stimulates cells through a toll-like receptors (TLR) 7 and 8 dependent pathway resulting in activation of immune responses that …
Resiquimod: Uses, Interactions, Mechanism of Action - DrugBank …
2008年3月19日 · Resiquimod is a Toll-like receptor 7 (TLR7) and TLR8 agonist that is a potent inducer of alpha interferon (IFN-alpha) and other cytokines.
Resiquimod: a new topical immune-response modifier for the ... - PubMed
2021年11月15日 · Resiquimod is a Toll-like receptor (TLR)-7 and TLR-8 agonist that, like imiquimod, belongs to the class of imidazoquinolines, small organic molecules with potent …
Full article: Resiquimod: a new topical immune-response modifier …
2021年11月15日 · Resiquimod is a Toll-like receptor (TLR)-7 and TLR-8 agonist that activates myeloid and plasmacytoid dendritic cells. In addition, resiquimod may promote the release of …
Resiquimod | C17H22N4O2 | CID 159603 - PubChem
Resiquimod is an imidazoquinolinamine and Toll-like receptor (TLR) agonist with potential immune response modifying activity. Resiquimod exerts its effect through the TLR signaling …
A New Topical Treatment for Cutaneous T-Cell Lymphoma
The investigational topical drug resiquimod was safe and effective in clearing treated and untreated skin lesions in patients with early-stage cutaneous T-cell lymphoma (CTCL), …
Resiquimod—a topical CTCL therapy | Nature Reviews Clinical …
2015年8月25日 · However, resiquimod, a Toll-like receptor 7/8 (TLR7/8) agonist, has now shown curative potential in a phase I trial. “The highest response rates previously reported for topical …
Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 ...
To explore safety, pharmacokinetics, and pharmacodynamics of oral administration of resiquimod, a Toll-like receptor 7 and 8 agonist that induces endogenous interferon-alpha, in subjects with …
Intratumoral immunotherapy using platelet-cloaked ... - Nature
2021年3月31日 · Herein, we investigate whether localized delivery of the TLR agonist, resiquimod (R848), via platelet membrane-coated nanoparticles (PNP-R848) elicits antitumor responses.